Literature DB >> 6331295

Antibacterial activity of coumermycin alone and in combination with other antibiotics.

H C Neu, N X Chin, P Labthavikul.   

Abstract

Coumermycin has been shown to inhibit Staphylococcus aureus and Staphylococcus epidermidis strains that are susceptible and those that are resistant to methicillin at concentrations less than or equal to 0.05 micrograms/ml. Listeria monocytogenes and Corynebacterium spp. resistant to cephalosporins were inhibited by less than or equal to 1.6 micrograms of coumermycin ml, and streptococcal species, with the exception of Streptococcus faecalis, were inhibited by 0.1 micrograms/ml. Cross-resistance with beta-lactams or aminoglycosides was not found. Coumermycin acted synergistically with ofloxacin, norfloxacin, and enoxacin against S. aureus but did not show synergy when combined with nafcillin, vancomycin, or rifampin. Coumermycin did not inhibit members of the family Enterobacteriaceae or Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331295      PMCID: PMC185623          DOI: 10.1128/AAC.25.6.687

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Pharmacokinetic profile of coumermycin A.

Authors:  S A Kaplan
Journal:  J Pharm Sci       Date:  1970-03       Impact factor: 3.534

2.  Antistaphylococcal activity of rifampin with other antibiotics.

Authors:  S H Zinner; H Lagast; J Klastersky
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

3.  The emergence of methicillin-resistant Staphylococcus aureus.

Authors:  R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

4.  Antibiotic-resistant group JK bacteria in hospitals.

Authors:  V J Gill; C Manning; M Lamson; P Woltering; P A Pizzo
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

5.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

6.  Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.

Authors:  D C Hooper; J S Wolfson; G L McHugh; M B Winters; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes.

Authors:  D J Winston; W G Ho; R P Gale
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

  7 in total
  12 in total

Review 1.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Vancomycin for treatment of infections with methicillin-resistant Staphylococcus aureus: are there alternatives?

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

4.  Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.

Authors:  K Machka; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

Review 5.  Listeria monocytogenes infections--therapeutic possibilities and problems.

Authors:  W Marget; H P Seeliger
Journal:  Infection       Date:  1988       Impact factor: 3.553

6.  Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.

Authors:  Neil R Stokes; Helena B Thomaides-Brears; Stephanie Barker; James M Bennett; Joanne Berry; Ian Collins; Lloyd G Czaplewski; Vicki Gamble; Paul Lancett; Alastair Logan; Christopher J Lunniss; Hilary Peasley; Stéphanie Pommier; Daniel Price; Carol Smee; David J Haydon
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

7.  Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method.

Authors:  J A Patel; C T Pachucki; J R Lentino
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Comparative in vitro activity of coumermycin against methicillin-resistant Staphylococcus aureus.

Authors:  B R Meyers; E S Srulevitch; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.

Authors:  K E Aldridge; A Janney; C V Sanders
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

Review 10.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.